Suicidal individuals with depression likely have diminished capacity to provide informed consent for treatment as well as low perceived need for help.
News
These results were instrumental in securing the FDA approval of the drug for the treatment of schizophrenia in adults in April 2023.
Why aren't psychiatrists the answer?
New positive data for brexpiprazole, the first and only treatment approved to treat agitation associated with dementia due to Alzheimer disease.
What does it mean to receive crisis care in the typical emergency department? Psychiatrists have a powerful role in reducing boarding.
This book offers positivity via a unique form of poetry.
What are your gender pronouns?
From sleep and neuroendocrine function following TBI to new phase 3 results from a clinical trial evaluating a promising new schizophrenia treatment, here are highlights from the week in Psychiatric Times.
What is new in research on SUDs?
Is the world safe for our grandchildren?
Remembering Eugene Paykel, MD…
Sleep and neuroendocrine function are disrupted following TBI.
Researchers performed a head-to-head trial of vortioxetine versus desvenalfaxine in patients with depression and partial response to SSRIs.
Happy Halloween! To celebrate, Psychiatric Times® is looking back at our Scariest in Psychiatry series, which highlights clinicians’ most frightening, worrisome, and concerning issues in psychiatry.
Just because a patient has anxiety or past trauma does not mean they cannot enjoy this spooky holiday…
We must come together to find peace, says one doctor.
Researchers investigated associations between medications with potential depressive symptom adverse effects and the level of depressive symptoms in a large survey study. Here’s what they found.
The trial’s results showed statistically significant reductions in all major symptom domains and secondary endpoints.
Are you ready for Halloween? Who is your favorite slash killer of the horror genre and which psychiatric disorder could he meet criteria for?
Whenever the Jewish people are targeted historically, the risk spreads to vulnerable others.
The experts weighed in on a wide variety of psychiatric issues for the October 2023 issue of Psychiatric Times.
A psychiatrist reflects on the latest shootings.
From deep brain stimulation for treatment-resistant schizophrenia to a look at the potential trajectory of artificial intelligence in psychiatry and medicine, here are highlights from the week in Psychiatric Times.
Discover how this thought-provoking novelette by a psychiatrist weaves rich characters, a suspenseful plot, and profound insights, leaving readers pondering the complex questions it raises about God, violence, and human compassion—and feeling moved.
Here are some updates from the world of psychiatry throughout the month of October.
What is new in research on TMS?
Positive results were just released from 2 phase 3 clinical trials evaluating centanafadine for the treatment of adolescents and children with ADHD.
In this CME article, review literature on SRI-related bleeding complications in patients with GI bleeding, malignancy, perioperative settings, pregnancy, and hormonal therapy.
The mental health workforce remains predominantly White, despite slight progress towards more diversity. Here’s how we can remove barriers for individuals of color who wish to enter the mental health field.
Psychiatry should increase knowledge of interventions to decrease “evil”…
Advertisement
Advertisement